Cigna Group (CI) Stock Analysis and Metrics

Cigna

NYSE: CI

$289.72 ▲ +3.43 (+1.20%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap75.16 Bn

P/E11.50

P/S0.75

Div. Yield0.02

ROIC (Qtr)0.01

Total Debt (Qtr)30.90 Bn

Revenue Growth (1y) (Qtr)-85.02

Add ratio to table…

About

The Cigna Group is a global health company that provides health services and solutions to improve the health and vitality of individuals and communities. It serves approximately 185 million customer relationships across more than 30 markets and employs about 67,700 people worldwide.

The company generates revenue primarily from fees for pharmacy benefit management, specialty pharmacy and care services, and from premiums and administrative fees for medical and health insurance plans.

The company operates through the following segments: Evernorth Health Services and Cigna Healthcare.

• Evernorth Health Services: This segment provides pharmacy benefit services including claims adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, formulary management, medical drug management, group purchasing organization administration, value based programs, home delivery pharmacy and specialty pharmacy services such as Accredo, health system distribution through CuraScript SD and care services including virtual care and behavioral health support.

• Cigna Healthcare: This segment offers comprehensive medical and coordinated solutions through its U. S. Healthcare and International Health operations, providing employer medical plans, individual and family plans, consumer directed products, behavioral health services, consumer health engagement programs, cost containment initiatives, dental products, pharmacy management services leveraging Evernorth, stop loss insurance for self funded groups and international health coverage including medical dental pharmacy vision life and disability risks for multinational employers and globally mobile individuals.

The Cigna Group holds a strong position in the health care industry as one of the largest integrated health service providers in the United States and competes with major firms such as UnitedHealth Group, CVS Health and Elevance Health. Its competitive advantages stem from the combination of pharmacy benefit management and medical insurance capabilities, extensive provider networks, advanced data analytics and a focus on affordability and transparency.

The company serves a diverse customer base that includes managed care organizations, health insurers, third party administrators, employers, union sponsored benefit plans, workers' compensation programs, government health programs, providers, clinics and hospitals. Specific customers named in the filing include Express Scripts, Centene Corporation, Prime Therapeutics LLC and the TRICARE program of the Department of Defense.

Investment Thesis

▲ Bull case

Cigna Group is positioned for sustained margin expansion through the accelerating adoption of biosimilars and specialty generics within its Specialty and Care Services platform, driven by strategic $0 out-of-pocket pricing initiatives for high-cost biologics like HUMIRA and STELARA. These initiatives, reinforced by AI-enabled patient identification and conversion strategies, are not only increasing volume but also shifting the therapy mix toward more cost-effective alternatives, thereby lowering reported revenue while supporting higher pretax margins. Management noted that biosimilar adoption contributed to a 20% year-over-year increase in Specialty and Care Services pretax adjusted earnings, with additional upside expected from generic Revlimid supply easing later in 2026. The integration of data, advanced analytics, and Agentic AI enables personalized conversion pathways that yield high patient adherence and satisfaction, creating a durable competitive advantage in managing complex, high-cost therapies. This structural shift toward biosimilars is not a temporary tactic but a secular trend that aligns with employer affordability goals and positions Cigna to capture growing demand in specialty pharmacy, where secular growth rates are mid- to high single digits and Cigna’s differentiated capabilities in supply chain, clinical support, and inventory management allow it to outperform. The Shields Health Solutions investment further enhances hospital and health system partnerships, creating synergies that expand Cigna’s reach in infused specialty drugs and 340B optimization, which remains underappreciated by the market as a scalable, high-margin growth vector. As biosimilar penetration accelerates across therapeutic areas, Cigna’s early mover advantage in incentive-aligned, patient-centric conversion models could drive sustained specialty margin expansion beyond current expectations.
The transformative "Signature" rebate-free pharmacy benefit model represents a multi-year investment that is underappreciated as a near-term catalyst, with client retention and new business wins signaling strong foundational traction ahead of its 2028 scaled launch. Despite Pharmacy Benefit Services pretax adjusted earnings declining 28% year-over-year due to transition investments and large client renewals, management emphasized over 97% year-end client retention in Evernorth PBS and mid-90s retention targets for the 2027 selling season, indicating exceptional client loyalty during a period of model evolution. The company secured key new business wins for 2027, underscoring that current solutions are resonating in the market while preparing clients for the future transition. The "Signature" model’s core value proposition—delivering brand drug prices 30% lower with full transparency—addresses the industry’s most pressing pain point: affordability of high-cost branded prescriptions, which represent 10% of volume but nearly 90% of drug spending. AI integration in member communication and notification systems enhances the patient experience without clinical decision-making, preserving trust while improving operational efficiency, as evidenced by a 20% drop in inbound calls for digitally eligible U.S. employer customers and a 25% reduction for PBS members over two years. With the ramp-up of transition spending weighted toward the second half of 2026 and the model becoming standard in 2028, early adoption signals suggest that at least 50% PBS member conversion by year-end 2028 is achievable, potentially unlocking significant long-term margin improvement and differentiation in a commoditized PBM landscape.
Cigna Healthcare’s Medical Care Ratio (MCR) of 79.8% in Q1 FY26, below both prior guidance and the full-year range of 83.7% to 84.7%, reflects structural advantages beyond temporary factors like flu season and weather-related deferrals, supported by favorable product mix shifts and persistent execution in employer groups. While management acknowledged lower flu volumes and weather-related care deferrals aided results, they also noted a higher proportion of individual exchange members enrolled in bronze plans—which carry lower MCRs early in the year—and emphasized that cost trends remain elevated and were priced into expectations. The outperformance occurred despite these headwinds, suggesting underlying strength in risk prediction models, preventive care initiatives, and site-of-care optimization. AI-driven predictive high-cost claimant identification is delivering approximately $2,000 per member per year in savings by reducing unnecessary provider and ER visits, with applications expanding into stop-loss business and broader clinical engagement. Combined with the success of the Clearity co-pay-only medical plan—externally derived clinical quality measures, single digital front door via myCigna app—and Cigna Healthcare’s #1 ranking in J.D. Power digital experience satisfaction for two consecutive years, these factors indicate a deeper capability to manage utilization and improve affordability. The ability to consistently deliver MCR below guided ranges, even amid elevated cost trends, signals underappreciated operational excellence in medical cost management that could support sustained earnings resilience and multiple expansion if trends persist.

Cigna Group is positioned for sustained margin expansion through the accelerating adoption of biosimilars and specialty generics within its Specialty and Care Services platform, driven by strategic $0 out-of-pocket pricing initiatives for high-cost biologics like HUMIRA and STELARA. These initiatives, reinforced by AI-enabled patient identification and conversion strategies, are not only increasing volume but also shifting the therapy mix toward more cost-effective alternatives, thereby lowering reported revenue while supporting higher pretax margins. Management noted that biosimilar adoption contributed to a 20% year-over-year increase in Specialty and Care Services pretax adjusted earnings, with additional upside expected from generic Revlimid supply easing later in 2026. The integration of data, advanced analytics, and Agentic AI enables personalized conversion pathways that yield high patient adherence and satisfaction, creating a durable competitive advantage in managing complex, high-cost therapies. This structural shift toward biosimilars is not a temporary tactic but a secular trend that aligns with employer affordability goals and positions Cigna to capture growing demand in specialty pharmacy, where secular growth rates are mid- to high single digits and Cigna’s differentiated capabilities in supply chain, clinical support, and inventory management allow it to outperform. The Shields Health Solutions investment further enhances hospital and health system partnerships, creating synergies that expand Cigna’s reach in infused specialty drugs and 340B optimization, which remains underappreciated by the market as a scalable, high-margin growth vector. As biosimilar penetration accelerates across therapeutic areas, Cigna’s early mover advantage in incentive-aligned, patient-centric conversion models could drive sustained specialty margin expansion beyond current expectations.
The transformative "Signature" rebate-free pharmacy benefit model represents a multi-year investment that is underappreciated as a near-term catalyst, with client retention and new business wins signaling strong foundational traction ahead of its 2028 scaled launch. Despite Pharmacy Benefit Services pretax adjusted earnings declining 28% year-over-year due to transition investments and large client renewals, management emphasized over 97% year-end client retention in Evernorth PBS and mid-90s retention targets for the 2027 selling season, indicating exceptional client loyalty during a period of model evolution. The company secured key new business wins for 2027, underscoring that current solutions are resonating in the market while preparing clients for the future transition. The "Signature" model’s core value proposition—delivering brand drug prices 30% lower with full transparency—addresses the industry’s most pressing pain point: affordability of high-cost branded prescriptions, which represent 10% of volume but nearly 90% of drug spending. AI integration in member communication and notification systems enhances the patient experience without clinical decision-making, preserving trust while improving operational efficiency, as evidenced by a 20% drop in inbound calls for digitally eligible U.S. employer customers and a 25% reduction for PBS members over two years. With the ramp-up of transition spending weighted toward the second half of 2026 and the model becoming standard in 2028, early adoption signals suggest that at least 50% PBS member conversion by year-end 2028 is achievable, potentially unlocking significant long-term margin improvement and differentiation in a commoditized PBM landscape.
Cigna Healthcare’s Medical Care Ratio (MCR) of 79.8% in Q1 FY26, below both prior guidance and the full-year range of 83.7% to 84.7%, reflects structural advantages beyond temporary factors like flu season and weather-related deferrals, supported by favorable product mix shifts and persistent execution in employer groups. While management acknowledged lower flu volumes and weather-related care deferrals aided results, they also noted a higher proportion of individual exchange members enrolled in bronze plans—which carry lower MCRs early in the year—and emphasized that cost trends remain elevated and were priced into expectations. The outperformance occurred despite these headwinds, suggesting underlying strength in risk prediction models, preventive care initiatives, and site-of-care optimization. AI-driven predictive high-cost claimant identification is delivering approximately $2,000 per member per year in savings by reducing unnecessary provider and ER visits, with applications expanding into stop-loss business and broader clinical engagement. Combined with the success of the Clearity co-pay-only medical plan—externally derived clinical quality measures, single digital front door via myCigna app—and Cigna Healthcare’s #1 ranking in J.D. Power digital experience satisfaction for two consecutive years, these factors indicate a deeper capability to manage utilization and improve affordability. The ability to consistently deliver MCR below guided ranges, even amid elevated cost trends, signals underappreciated operational excellence in medical cost management that could support sustained earnings resilience and multiple expansion if trends persist.

▼ Bear case

Cigna Group’s Pharmacy Benefit Services (PBS) segment faces significant near-term margin pressure and execution risk as the transition to the rebate-free "Signature" model intensifies, with pretax adjusted earnings declining 28% year-over-year in Q1 FY26 and management confirming that transition spending is weighted toward the second half of 2026. The $150 million year-over-year earnings decline in PBS was explicitly attributed to proactive large client renewals and investments in the new model, with CFO Dennison noting that the trajectory remains consistent with prior commentary but offers no near-term relief. While client retention remains strong at over 97% year-end and mid-90s targets are set for 2027, the model’s success hinges on achieving at least 50% PBS member conversion by end-2028—a timeline that leaves significant uncertainty over client willingness to migrate, especially given the complexity of replacing entrenched rebate-based contracts. The model’s reliance on AI for member communication and notification, rather than clinical decision-making, limits its ability to directly influence prescribing behavior or drug selection, potentially constraining its impact on net drug costs beyond transparency and pricing guarantees. Furthermore, the ongoing lawsuit by Express Scripts against Tennessee’s FAIR Rx Act—which prohibits PBM-owned pharmacies from dispensing medications—poses a material regulatory risk; if similar laws spread to other states, they could disrupt Cigna’s integrated pharmacy model, particularly its Accredo specialty pharmacy and mail-order operations, which are central to the "Signature" value proposition. The market may be underestimating the regulatory and operational headwinds that could delay or diminish the expected benefits of this transformation.
Despite strong specialty growth, Cigna Group’s reliance on biosimilar adoption as a margin lever carries inherent volatility and execution risk, particularly as biosimilar uptake remains uneven across therapeutic areas and is highly sensitive to formulary changes, patient physician inertia, and ongoing legal challenges from originator biologics companies. While management highlighted growth in severe asthma, hepatology, and fertility segments, the contribution from biosimilars like STELARA—available $0 out-of-pocket only since May 2025—means year-over-year comparisons are artificially inflated due to lapping a period when the product was not yet offered, creating a base effect that may not persist. The company’s investment in Shields Health Solutions and acquisition of CarepathRx aim to enhance hospital partnerships and infusion capabilities, but these ventures introduce integration risk and dilute focus, with noncontrolling interest rising sharply—$226 million in Q1 FY26, more than doubling versus Q1 FY25—driven largely by a new joint venture with a large client where most economics are passed back, masking true profitability. The CFO acknowledged that despite holding a majority stake, most of the economics in this JV are passed back to partners, meaning the reported NCI growth does not translate to incremental earnings for Cigna. Furthermore, biosimilar adoption, while reducing drug costs and improving affordability, also lowers reported revenue in the Specialty and Care Services segment, creating a potential misalignment between top-line growth and profitability if volume gains do not fully offset pricing pressure. The market may be overestimating the scalability and margin expansion potential of biosimilars without sufficient visibility into net contribution after rebates, fees, and network costs.
Cigna Healthcare’s favorable Medical Care Ratio (MCR) of 79.8% in Q1 FY26, while impressive, may reflect temporary and non-recurring factors that are unlikely to persist, with management acknowledging that lower flu volumes and weather-related care deferrals contributed to the outperformance, and the full-year MCR guidance range of 83.7% to 84.7% remains unchanged. The shift toward bronze plan enrollment in the individual exchange business—cited as a factor in lower early-year MCR—is not sustainable given the company’s planned exit from the individual exchange at year-end 2026, which will remove this mix benefit entirely. Additionally, while AI-driven predictive models for high-cost claimants are yielding approximately $2,000 per member per year in savings, these savings are contingent on consistent patient engagement and clinical team follow-through, and there is no evidence yet that these programs are scaling broadly enough to meaningfully impact the overall medical cost trend. The company’s continued expectation of elevated cost trends—despite no near-term deceleration—suggests that the Q1 outperformance may be an anomaly rather than a trend, especially as the seasonal reversal from Q1 to Q2 is expected to be steeper this year due to the absence of the flatter MCR seasonality from the divested Medicare business and the steeper pattern from higher bronze plan enrollment in the individual segment. If medical cost trends remain elevated and utilization rebounds in higher-acuity services, the current MCR advantage could evaporate quickly, leaving Cigna Healthcare exposed to margin compression without a clear offsetting lever in sight.

Cigna Group’s Pharmacy Benefit Services (PBS) segment faces significant near-term margin pressure and execution risk as the transition to the rebate-free "Signature" model intensifies, with pretax adjusted earnings declining 28% year-over-year in Q1 FY26 and management confirming that transition spending is weighted toward the second half of 2026. The $150 million year-over-year earnings decline in PBS was explicitly attributed to proactive large client renewals and investments in the new model, with CFO Dennison noting that the trajectory remains consistent with prior commentary but offers no near-term relief. While client retention remains strong at over 97% year-end and mid-90s targets are set for 2027, the model’s success hinges on achieving at least 50% PBS member conversion by end-2028—a timeline that leaves significant uncertainty over client willingness to migrate, especially given the complexity of replacing entrenched rebate-based contracts. The model’s reliance on AI for member communication and notification, rather than clinical decision-making, limits its ability to directly influence prescribing behavior or drug selection, potentially constraining its impact on net drug costs beyond transparency and pricing guarantees. Furthermore, the ongoing lawsuit by Express Scripts against Tennessee’s FAIR Rx Act—which prohibits PBM-owned pharmacies from dispensing medications—poses a material regulatory risk; if similar laws spread to other states, they could disrupt Cigna’s integrated pharmacy model, particularly its Accredo specialty pharmacy and mail-order operations, which are central to the "Signature" value proposition. The market may be underestimating the regulatory and operational headwinds that could delay or diminish the expected benefits of this transformation.
Despite strong specialty growth, Cigna Group’s reliance on biosimilar adoption as a margin lever carries inherent volatility and execution risk, particularly as biosimilar uptake remains uneven across therapeutic areas and is highly sensitive to formulary changes, patient physician inertia, and ongoing legal challenges from originator biologics companies. While management highlighted growth in severe asthma, hepatology, and fertility segments, the contribution from biosimilars like STELARA—available $0 out-of-pocket only since May 2025—means year-over-year comparisons are artificially inflated due to lapping a period when the product was not yet offered, creating a base effect that may not persist. The company’s investment in Shields Health Solutions and acquisition of CarepathRx aim to enhance hospital partnerships and infusion capabilities, but these ventures introduce integration risk and dilute focus, with noncontrolling interest rising sharply—$226 million in Q1 FY26, more than doubling versus Q1 FY25—driven largely by a new joint venture with a large client where most economics are passed back, masking true profitability. The CFO acknowledged that despite holding a majority stake, most of the economics in this JV are passed back to partners, meaning the reported NCI growth does not translate to incremental earnings for Cigna. Furthermore, biosimilar adoption, while reducing drug costs and improving affordability, also lowers reported revenue in the Specialty and Care Services segment, creating a potential misalignment between top-line growth and profitability if volume gains do not fully offset pricing pressure. The market may be overestimating the scalability and margin expansion potential of biosimilars without sufficient visibility into net contribution after rebates, fees, and network costs.
Cigna Healthcare’s favorable Medical Care Ratio (MCR) of 79.8% in Q1 FY26, while impressive, may reflect temporary and non-recurring factors that are unlikely to persist, with management acknowledging that lower flu volumes and weather-related care deferrals contributed to the outperformance, and the full-year MCR guidance range of 83.7% to 84.7% remains unchanged. The shift toward bronze plan enrollment in the individual exchange business—cited as a factor in lower early-year MCR—is not sustainable given the company’s planned exit from the individual exchange at year-end 2026, which will remove this mix benefit entirely. Additionally, while AI-driven predictive models for high-cost claimants are yielding approximately $2,000 per member per year in savings, these savings are contingent on consistent patient engagement and clinical team follow-through, and there is no evidence yet that these programs are scaling broadly enough to meaningfully impact the overall medical cost trend. The company’s continued expectation of elevated cost trends—despite no near-term deceleration—suggests that the Q1 outperformance may be an anomaly rather than a trend, especially as the seasonal reversal from Q1 to Q2 is expected to be steeper this year due to the absence of the flatter MCR seasonality from the divested Medicare business and the steeper pattern from higher bronze plan enrollment in the individual segment. If medical cost trends remain elevated and utilization rebounds in higher-acuity services, the current MCR advantage could evaporate quickly, leaving Cigna Healthcare exposed to margin compression without a clear offsetting lever in sight.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Healthcare Plans

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	UNH	Unitedhealth Group Inc	384.70 Bn	30.02	0.90	77.92 Bn
2	CVS	CVS HEALTH Corp	136.05 Bn	46.86	1.84	63.11 Bn
3	ELV	Elevance Health, Inc.	82.25 Bn	16.64	0.45	31.04 Bn
4	CI	Cigna Group	75.16 Bn	11.50	0.75	30.90 Bn
5	HUM	Humana Inc	47.47 Bn	38.91	0.46	13.99 Bn
6	CNC	Centene Corp	31.35 Bn	-4.86	0.17	16.37 Bn
7	MOH	Molina Healthcare, Inc.	10.44 Bn	54.34	0.24	3.77 Bn
8	OSCR	Oscar Health, Inc.	8.62 Bn	-218.95	1.15	0.43 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password